Serina Therapeutics Inc. reported operating expenses of $6.4 million for the third quarter ended September 30, 2025, up from $5.3 million in the same period of 2024. General and administrative expenses were $2.7 million, compared to $2.9 million in the prior year, mainly due to reduced compensation costs partially offset by increased investor outreach expenses. Other income was $1.8 million, down from $6.7 million last year, primarily due to changes in the fair value of liability classified warrants, partially offset by gains from warrant expirations. The company reported a net loss of $4.6 million, or $0.45 per basic and diluted share, compared to net income of $1.4 million, or $0.16 per basic share and $0.13 per diluted share, in 2024. During the quarter, Serina launched a new corporate communications platform and continued its at-the-market equity program, issuing 474,712 shares at an average price of $6.00, raising $2.8 million in net proceeds. The company also highlighted FDA alignment on the advancement of its lead drug candidate, SER-252, under the 505(b)(2) NDA pathway.